Literature DB >> 34914062

Development of the Antileishmanial Vaccine.

Sunil Kumar1, Shubhranshu Zutshi1, Mukesh Kumar Jha1,2, Prashant Chauhan1, Bhaskar Saha3,4.   

Abstract

Search for an efficacious antileishmanial vaccine has led to clinical trials of numerous vaccine candidates in the past few decades. As no promising candidate has emerged from these studies, novel vaccine modalities and vaccine assessment techniques are still emerging for antileishmanial vaccine development. Briefly, this chapter discusses: (a) history and timeline of antileishmanial vaccine development; (b) techniques utilized for developing whole-parasite and subunit-based antileishmanial vaccine formulations, and (c) immunogenicity and post-challenge protective efficacy assessment of vaccine candidates.
© 2022. The Author(s), under exclusive license to Springer Science+Business Media, LLC, part of Springer Nature.

Entities:  

Keywords:  Antileishmanial vaccine; Electroporation; Flow cytometry; Immunogenicity; Mass spectrometry; Ni-NTA affinity chromatography; Parasite load; T-helper response

Mesh:

Substances:

Year:  2022        PMID: 34914062     DOI: 10.1007/978-1-0716-1884-4_23

Source DB:  PubMed          Journal:  Methods Mol Biol        ISSN: 1064-3745


  48 in total

Review 1.  The life-cycle of Leishmania in the sandfly with special reference to the form infective to the vertebrate host.

Authors:  R Killick-Kendrick
Journal:  Ann Parasitol Hum Comp       Date:  1990

2.  Leishmanization: use of an old method for evaluation of candidate vaccines against leishmaniasis.

Authors:  Ali Khamesipour; Yahya Dowlati; Ali Asilian; Reza Hashemi-Fesharki; Amir Javadi; Sassan Noazin; Farrokh Modabber
Journal:  Vaccine       Date:  2005-05-25       Impact factor: 3.641

3.  Study of the safety, immunogenicity and efficacy of attenuated and killed Leishmania (Leishmania) major vaccines in a rhesus monkey (Macaca mulatta) model of the human disease.

Authors:  V F Amaral; A Teva; M P Oliveira-Neto; A J Silva; M S Pereira; E Cupolillo; R Porrozzi; S G Coutinho; C Pirmez; S M Beverley; G Grimaldi
Journal:  Mem Inst Oswaldo Cruz       Date:  2002-10       Impact factor: 2.743

Review 4.  Leishmaniasis: current status of vaccine development.

Authors:  E Handman
Journal:  Clin Microbiol Rev       Date:  2001-04       Impact factor: 26.132

5.  Evaluation of the stability and immunogenicity of autoclaved and nonautoclaved preparations of a vaccine against American tegumentary leishmaniasis.

Authors:  P M De Luca; W Mayrink; C R Alves; S G Coutinho; M P Oliveira; A L Bertho; V P Toledo; C A Costa; O Genaro; S C Mendonça
Journal:  Vaccine       Date:  1999-03-05       Impact factor: 3.641

6.  Green fluorescent protein-tagged Leishmania in phlebotomine sand flies.

Authors:  P Guevara; D Pinto-Santíni; A Rojas; G Crisante; N Añez; J L Ramirez
Journal:  J Med Entomol       Date:  2001-01       Impact factor: 2.278

7.  Pathogenicity and protective immunogenicity of cysteine proteinase-deficient mutants of Leishmania mexicana in non-murine models.

Authors:  Nancy Gore Saravia; Blanca Escorcia; Yaneth Osorio; Liliana Valderrama; Darren Brooks; Lourdes Arteaga; Graham Coombs; Jeremy Mottram; Bruno Luis Travi
Journal:  Vaccine       Date:  2005-10-10       Impact factor: 3.641

8.  Vaccination using live attenuated Leishmania donovani centrin deleted parasites induces protection in dogs against Leishmania infantum.

Authors:  Jacqueline Araújo Fiuza; Sreenivas Gannavaram; Helton da Costa Santiago; Angamuthu Selvapandiyan; Daniel Menezes Souza; Lívia Silva Araújo Passos; Ludmila Zanandreis de Mendonça; Denise da Silveira Lemos-Giunchetti; Natasha Delaqua Ricci; Daniella Castanheira Bartholomeu; Rodolfo Cordeiro Giunchetti; Lilian Lacerda Bueno; Rodrigo Correa-Oliveira; Hira L Nakhasi; Ricardo Toshio Fujiwara
Journal:  Vaccine       Date:  2014-12-01       Impact factor: 3.641

9.  Live attenuated Leishmania donovani p27 gene knockout parasites are nonpathogenic and elicit long-term protective immunity in BALB/c mice.

Authors:  Ranadhir Dey; Pradeep K Dagur; Angamuthu Selvapandiyan; J Philip McCoy; Poonam Salotra; Robert Duncan; Hira L Nakhasi
Journal:  J Immunol       Date:  2013-01-21       Impact factor: 5.422

Review 10.  First generation leishmaniasis vaccines: a review of field efficacy trials.

Authors:  Sassan Noazin; Farrokh Modabber; Ali Khamesipour; Peter G Smith; Lawrence H Moulton; Kiumarss Nasseri; Iraj Sharifi; Eltahir A G Khalil; Ivan Dario Velez Bernal; Carlos M F Antunes; Marie Paule Kieny; Marcel Tanner
Journal:  Vaccine       Date:  2008-10-23       Impact factor: 3.641

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.